The American Journal of Medicine
Volume 121, Issue 7 , Pages 562-564 , July 2008

Perspectives on “Chronic Lyme Disease”

  • Phillip J. Baker, PhD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Phillip J. Baker, PhD, Post Office Box 466, Lyme, CT 06371.

References 

  1. Klempner MS, Hu LT, Evans J, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med. 2001;345:85–92
  2. Krupp LB, Hyman LG, Grimson , et al. Study and treatment of post Lyme disease (stop-LD): a randomized double-masked clinical trial. Neurology. 2003;60:1923–1930
  3. Patel R, Grogg KL, Edwards WD, et al. Death from inappropriate therapy for Lyme disease. Clin Infect Dis. 2000;31:1107–1109
  4. Shaffer EA. Gall bladder sludge: what is its clinical significance?. Curr Gastroenterol Rep. 2001;3:166–173
  5. Owens RC. Clostridium difficile-associated disease: an emerging threat to patient safety: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2006;26:299–311
  6. Moellering RC, Graybill JR, McGowan JE, et al. Antimicrobial resistance prevention initiative—an update: proceedings of an expert panel. Am J Med. 2007;120:S4–S25
  7. Sigal LH. Misconceptions about Lyme disease: confusions hiding behind ill-chosen terminology. Ann Intern Med. 2002;136:413–419
  8. Domercq M, Matute C. Neuroprotection by tetracyclines. Trends Pharmacol Sci. 2004;25:609–612
  9. Rothstein JD, Patel S, Regan MR, et al. β-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005;433:73–77
  10. Maier K, Merkler D, Gerber J, et al. Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation. Neurobiol Dis. 2007;25:514–525
  11. Weissenbacher S, Ring J, Hofman H. Gabapentin for the symptomatic treatment of chronic neuropathic pain in patients with late-stage Lyme borreliosis: a pilot study. Dermatology. 2005;211:123–127
  12. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43:1089–1134
  13. Halperin JJ, Shapiro ED, Logigian E, et al. Practice parameter: treatment of nervous system Lyme disease (an evidence-based review). Neurology. 2007;69:91–102
  14. Feder HM, Johnson BJB, O'Connell S, et al. A critical appraisal of “chronic Lyme disease.”. N Engl J Med. 2007;357:1422–1430

PII: S0002-9343(08)00181-2

doi: 10.1016/j.amjmed.2008.02.013

The American Journal of Medicine
Volume 121, Issue 7 , Pages 562-564 , July 2008

Article Tools